AIM2 and glioblastoma: As one of the few treatments for GBM that have demonstrated substantial survival benefit in clinical trials, tumor treating fields (TTFields) can activate stimulator of interferon genes (STING) and absent in melanoma 2 (AIM2) inflammasomes to trigger pyroptosis in tumor cells, which will then release tumor antigens and recruit dendritic cell (DCs) as well as tumor-specific cytotoxic T lymphocytes (CTLs), thus converting the TME into a pro-inflammatory environment [20].